Narcolepsy: New understanding of irresistible sleep

Mayo Clinic Proceedings

Volumn 76, Issue 2, 2001, Pages 185-194

  Krahn, Lois E ^a,b   Black, John L ^b,c   Silber, Michael H ^c  

^a Department of Psychiatry and Psychology ^*  (United States)

^b Sleep Disorders Center   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ALPHA ADRENERGIC RECEPTOR; CENTRAL STIMULANT AGENT; CLOMIPRAMINE; DEXAMPHETAMINE; FLUOXETINE; HLA DQ ANTIGEN; IMIPRAMINE; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; MONOAMINE; NEUROPEPTIDE; ORAL CONTRACEPTIVE AGENT; OREXIN A; OREXIN B; PAROXETINE; PEMOLINE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT;

ALCOHOLISM; CATAPLEXY; CLINICAL TRIAL; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DOG; DRUG INDUCED DISEASE; ELECTROENCEPHALOGRAM; HALLUCINATION; HEADACHE; HEART PALPITATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INSOMNIA; LATERAL HYPOTHALAMUS; MOUSE; NARCOLEPSY; NONHUMAN; PARASOMNIA; POLYSOMNOGRAPHY; PSYCHOPHARMACOLOGY; RAT; REM SLEEP; REVIEW; SLEEP APNEA SYNDROME; SLEEP DISORDER; SLEEP WAKING CYCLE; TREMOR;

EID: 0035150380     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/76.2.185     Document Type: Review

References (84)

1. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy [letter]. Lancet. 2000;355:39-40.
2. Siegel J. Brainstem mechanisms generating REM sleep. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia, Pa: WB Saunders Co Inc; 2000: 112-133.
3. Hobson JA, McCarley RW, Wyzinski PW. Sleep cycle oscillation: reciprocal discharge by two brainstem neuronal groups. Science. 1975;189:55-58.
4. Gelineau JBE. De la Narcolepsie. Lancette Fr. 1880;53:626-628.
5. Culebras A. Sleep and narcolepsy [published correction appears in Arch Neural 1999;56:632]. Arch Neurol. 1999;56:117-118.
6. Yoss RE, Daly DD. Criteria for the diagnosis of the narcoleptic syndrome. P roc Staff Meet Mayo Clin. 1957;32:320-328.
7. Vogel G. Studies in the psychophysiology of dreams, III: the dream of narcolepsy. Arch Gen Psychiatry. 1960;3:421-428.
8. Rechtschaffen A, Wolpert EA, Dement WC, Mitchell SA, Fisher C. Nocturnal sleep of narcoleptics. Electroencephalogr Clin Neurophysiol. 1963;15:599-609.
9. Broughton RJ, Guberman A, Roberts J. Comparison of the psychosocial effects of epilepsy and narcolepsy/cataplexy: a controlled study. Epilepsia. 1984;25:423-433.
10. Guilleminault C, Wilson RA, Dement WC. A study on cataplexy. Arch Neurol. 1974;31:255-261.
11. Siegel JM, Nienhuis R, Fahringer HM, et al. Neuronal activity in narcolepsy: identification of cataplexy-related cells in the medial medulla. Science. 1991:252:1315-1318.
12. Guilleminault C, Gelb M. Clinical aspects and features of cataplexy. Adv Neurol. 1995;67:65-77.
13. Hodes R. Effects of age, consciousness, and other factors on human electrically induced reflexes (EIRs). Electroencephalogr Clin Neurophysiol Suppl 1967:25:80-91.
14. Billiard M, Besset A, Cadilhac J. The clinical and polygraphic development of narcolepsy. In: Guilleminault C, Lugaresi E, eds. Sleep/Wake Disorders: Natural History, Epidemiology, and Longterm Evolution. New York, NY: Raven Press; 1983:171-185.
15. Schenck CH, Mahowald MW. Motor dyscontrol in narcolepsy: rapid-eye-movement (REM) sleep without atonia and REM sleep behavior disorder. Ann Neural 1992;32:3-10.
16. Mignot E, Hayduk R, Black J, Grumet FC, Guilleminault C. HLA DQB 1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep. 1997;20:1012-1020.
17. Anic-Labat S, Guilleminault C, Kraemer HC, Meehan J, Arrigoni J, Mignot E. Validation of a cataplexy questionnaire in 983 sleepdisorders patients. Sleep. 1999;22:77-87.
18. Johns MW. Sleepiness in different situations as measured by the Epworth Sleepiness Scale. Sleep. 1994; 17:703-710.
19. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991;14:540-545.
20. Sadeh A, Hauri PJ, Kripke DF, Lavie P. The role of actigraphy in the evaluation of sleep disorders. Sleep. 1995; 18:288-302.
21. Guilleminault C, Anagos A. Narcolepsy. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia, Pa: WB Saunders Co Inc; 2000:676-686.
22. Rechtschaffen A, Kales A, eds. A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. Bethesda, Md: US Dept of Health, Education, and Welfare; 1968. Publication 204.
23. Carskadon MA, Dement WC, Miller MM, Roth T, Westbrook PR, Keenan S. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep. 1986;9:519-524.
24. Doghramji K, Miller MM, Sangal RB, et al. A normalive sludy of ihe maintenance of wakefulness lesl (MWT). Electroencephalogr Clin Neurophysiol. 1997; 103:554-562.
25. Yoss RE, Moyer NJ, Ogle KN. The pupillogram and narcolepsy: a melhod lo measure decreased levels of wakefulness. Neurology. 1969; 19:921-928.
26. Dyken ME, Yamada T, Lin-Dyken DC, Seaba P, Yeh M. Diagnosing narcolepsy Ihrough ihe simullaneous clinical and eleclrophysiologic analysis of calaplexy. Arch Neural. 1996;53:456-460.
27. American Sleep Disorders Associalion. The International Classification of Sleep Disorders, Revised: Diagnostic and Coding Manual. Rochester, Minn: American Sleep Disorders Association; 1997.
28. Krahn L, Boeve B, Olson E, Herold D, Silber M. A standardized lesl for calaplexy. Sleep Med. 2000; 1:125-130.
29. Richardson JW, Fredrickson PA, Lin S-C. Narcolepsy update. Mayo Clin Proc. 1990;65:991-998.
30. Aldrich MS. The clinical speclrum of narcolepsy and idiopathic hypersomnia. Neurology. 1996;46:393-401.
31. Pelin Z, Guilleminaull C, Risch N, Grumel FC, Mignol E, US Modafinil in Narcolepsy Mullicenler Sludy Group. HLADQB 1*0602 homozygosily increases relalive risk for narcolepsy but nol disease severily in two ethnie groups. Tissue Antigens. 1998;51:96-100.
32. Mignol E. Genelic and familial aspecls of narcolepsy. Neurology. 1998;50(2, suppl 1):S16-S22.
33. Malik S, Silber M, Boeve B, Krahn L. Symplomalic (secondary) narcolepsy [abstract]. Sleep. 2000;23:A302.
34. Plazzi G, Montagna P, Provini F, Bizzi A, Cohen M, Lugaresi E. Ponline lesions in idiopalhic narcolepsy. Neurology. 1996;46: 1250-1254.
35. Basselli C, Aldrich MS, Quinl DJ. MRI findings in narcolepsy. Sleep. 1997:20:630-631.
36. Aldrich MS, Prokopowicz G, Ockert K, Hollingsworlh Z, Penney JB, Albin RL. Neurochemical sludies of human narcolepsy: alphaadrenergic receplor auloradiography of human narcoleplic brain and brainslem. Sleep. 1994; 17:598-608.
37. Aldrich MS, Hollingsworlh Z, Penney JB. Dopamine-receplor auloradiography of human narcoleptic brain. Neurology. 1992;42: 410-415.
38. Strittmatter M, Isenberg E, Grauer MT, Hamann G, Schimrigk K. CSF substance P somatostatin and monoaminergic transmitter metabolites in patients with narcolepsy. Neurosci Lett. 1996;218:99102.
39. Mayer G, Hellmann F, Leonhard E, Meier-Ewert K. Circadian temperature and activity rhythms in unmedicated narcoleptic patients. Pharmacol Biochem Behav. 1997;58:395-402.
40. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92:573-585.
41. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18:9996-10015.
42. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med. 2000;6:991-997.
43. Date Y, Ueta Y, Yamashita H, et al. Orexins, orexigenic hypothalamic peptides, interact with autonomie, neuroendocrine and neuroregulatory systems. Proc Natl Acad Sei U S A. 1999;96:748-753.
44. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999:98:365-376.
45. Kadotani H, Faraco J, Mignot E. Genetic studies in the sleep disorder narcolepsy. Genome Res. 1998;8:427-434.
46. John J, Wu M-F, Siegel JM. Systemic administration of hypocretin1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Res Online. 2000;3:23-28.
47. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999; 98:437-451.
48. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Compact 3rd ed. San Diego, Calif: Academic Press; 1997.
49. Nambu T, Sakurai T, Mizukami K, Hosoya Y, Yanagisawa M, Goto K. Distribution of orexin neurons in the adult rat brain. Brain Res. 1999:827:243-260.
50. Gautvik KM, de Lecea L, Gautvik VT, et al. Overview of the most prevalent hypothalamus-specific mRNAs, as identified by directional tag PCR subtraction. Proc Natl Acad Sei USA. 1996;93: 8733-8738.
51. Trivedi P, Yu H, MacNeil DJ, Van der Ploeg LH, Guan XM. Distribution of orexin receptor mRNA in the rat brain [published correction appears in FEBS Lett. 1999;442:122]. FEBS Lett. 1998; 438:71-75.
52. Broberger C, De Lecea L, Sutcliffe JG, Hokfelt T. Hypocretin/orexin- and melanin-concentrating hormone-expressing cells form distinct populations in the rodent lateral hypothalamus: relationship to the neuropeptide Y and agouti gene-related protein systems. J. Comp Neural. 1998;402:460-474.
53. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27:469-474.
54. Mignot E, Lin X, Arrigoni J, et al. DQB 1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep. 1994; 17(8, suppl):S60-S67.
55. Doyle JB, Daniels LE. Symptomatic treatment for narcolepsy. JAMA. 1931;96:1370-1372.
56. Prinzmetal M, Bloomberg W. The use of benzedrine for the treatment of narcolepsy. JAMA. 1935; 105:2051-2054.
57. Daly DD, Yoss RE. The treatment of narcolepsy with methyl phenylpiperidylacetate: a preliminary report. Proc Staff Meet Mayo Clin. 1956;31:620-626.
58. Parkes D. Introduction to the mechanism of action of different treatments of narcolepsy. Sleep. 1994; 17(8, suppl):S93-S96.
59. Mitler MM, Aldrich MS, Koob GF, Zarcone VP. Narcolepsy and its treatment with stimulants: ASDA standards of practice. Sleep. 1994; 17:352-371.
60. Engber TM, Koury EJ, Dennis SA, Miller MS, Contreras PC, Bhat RV. Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci Lett. 1998;241:95-98.
61. Daly DD, Yoss RE. Narcolepsy. In: Vinken PJ, Bruyn GW, eds. Handbook of Clinical Neurology. Vol 15. New York, NY: American Elsevier Publishing Co Inc; 1974:836-852.
62. Mitler MM, Hajdukovic R, Erman MK. Treatment of narcolepsy with methamphetamine. Sleep. 1993; 16:306-317.
63. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neural. 1998;43:88-97.
64. Parkes J, Baraitser M, Marsden C, Asselman P. Natural history, symptoms and treatment of the narcoleptic syndrome. Acta Neural Scand. 1975;52:337-353.
65. Rogers AE, Aldrich MS, Berrios AM, Rosenberg RS. Compliance with stimulant medications in patients with narcolepsy. Sleep. 1997;20:28-33.
66. Mitler MM, Erman M, Hajdukovic R. The treatment of excessive somnolence with stimulant drugs. Sleep. 1993;16:203-206.
67. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for excessive daytime somnolence in narcolepsy. Neurology. 2000;54:1166-1175.
68. Bassetti C, Aldrich MS. Narcolepsy. Neural Clin. 1996; 14:545571.
69. Littner M. Sleep practitioners need to be aware of new changes in the labeling of pemoline [letter]. Sleep. 1999;22:833.
70. Broughton RJ, Fleming JA, George CF, et al. Randomized, doubleblind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology. 1997;49:444-451.
71. Billiard M, Besset A, Montplaisir J, et al. Modafinil: a double-blind multicentric study. Sleep. 1994; 17(8, suppl):S107-Sl 12.
72. Besset A, Chetrit M, Carlander B, Billiard M. Use of modafinil in the treatment of narcolepsy: a long term follow-up study. NeurophysiolClin. 1996;26:60-66.
73. Mitler M, Harsh J, Hirshkowitz M, Guilleminault C, US Modafinil in Narcolepsy Multicenter Study Group. Long-term efficacy and safety of modafinil (Provigil) for the treatment of excessive daily sleepiness associated with narcolepsy. Sleep Med. 2000; 1:231 -243.
74. Mitler MM, Hajdukovic R. Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. Sleep. 1991; 14:218-220.
75. Mitler M, Hajdukovic R, Erman M, Koziol JA. Narcolepsy. J Clin Neurophysiol. 1990;7:93-118.
76. Modafinil for narcolepsy. Med Lett Drugs Ther. 1999;41:30-31.
77. Garma L, Marchand F. Non-pharmacological approaches to the treatment of narcolepsy. Sleep. 1994; 17(8, suppl):S97-S102.
78. Heimus T, Rosenthal L, Biship C, Roehrs T, Syron ML, Roth T. The alerting effects of short and long naps in narcoleptic, sleep deprived, and alert individuals. Sleep. 1997;20:251-257.
79. Mullington J, Broughton R. Scheduled naps in the management of daytime sleepiness in narcolepsy-cataplexy. Sleep. 1993; 16:444456.
80. Roehrs T, Zorick F, Wittig R, Paxton C, Sticklesteel J, Roth T. Alerting effects of naps in patients with narcolepsy. Sleep. 1986; 9(l,pt2):194-199.
81. Langdon N, Shindler J, Parkes JD, Bandak S. Fluoxetine in the treatment of cataplexy [letter]. Sleep. 1986;9:371-373.
82. Montplaisir J, Godbout R. Serotoninergic reuptake mechanisms in the control of cataplexy. Sleep. 1986;9(1, pt 2):280-284.
83. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol. 1997;52:27-78.
84. Thorpy MJ, Snyder M, Aloe FS, Ledereich PS, Starz KE. Shortterm triazolam use improves nocturnal sleep of narcoleptics. Sleep. 1992;15:212-216.